A three-dimensional model of the AT1 receptor was constructed by means of a homology modeling procedure, using the X-ray structure of bovine rhodopsin as the initial template and taking into account the available site-directed mutagenesis data. The docking of losartan and its active metabolite EXP3174, followed by 1 ns of molecular dynamics (MD) simulation inserted into the phospholipid bilayer, suggested a different binding orientation for these antagonists from those previously proposed. Furthermore, the docking of several non-peptide antagonists was used as an alignment tool for the development of a three-dimensional quantitative structure-activity relationship (3D-QSAR) model, and the good results confirmed our binding hypothesis and th...
The number of solved G-protein-coupled receptor (GPCR) crystal structures has expanded rapidly, but ...
<p>When a small molecule binds to the androgen receptor (AR), a conformational change can occur whic...
While the molecular structures of angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) are ...
A 3D-QSAR model using the GRIND/ALMOND descriptors has been performed on a set of 49 angiotensin rec...
As a continuing effort to establish the structure-activity relationships (SARs) within the series of...
The integration of ligand- and structure-based strategies might sensitively increase the success of ...
As a continuing effort to establish the structure-activity relationships (SARs) within the series of...
The recent availability of crystal structure of bovine rhodopsin offers new opportunities in order t...
A computer-aided approach has been developed in order to understand the molecular pharmacology of hu...
Novel AT1 receptor antagonists bearing substituted 4-phenylquinoline moieties instead of theclassica...
We present a combined computational study aimed at identifying the three-dimensional structural prop...
We present a combined computational study aimed at identifying the three-dimensional structural prop...
Rational conversion of biologically active peptides to nonpeptide compounds with retained activity i...
AbstractThe drug:membrane interactions for the antihypertensive AT1 antagonist losartan, the prototy...
When a small molecule binds to the androgen receptor (AR), a conformational change can occur which i...
The number of solved G-protein-coupled receptor (GPCR) crystal structures has expanded rapidly, but ...
<p>When a small molecule binds to the androgen receptor (AR), a conformational change can occur whic...
While the molecular structures of angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) are ...
A 3D-QSAR model using the GRIND/ALMOND descriptors has been performed on a set of 49 angiotensin rec...
As a continuing effort to establish the structure-activity relationships (SARs) within the series of...
The integration of ligand- and structure-based strategies might sensitively increase the success of ...
As a continuing effort to establish the structure-activity relationships (SARs) within the series of...
The recent availability of crystal structure of bovine rhodopsin offers new opportunities in order t...
A computer-aided approach has been developed in order to understand the molecular pharmacology of hu...
Novel AT1 receptor antagonists bearing substituted 4-phenylquinoline moieties instead of theclassica...
We present a combined computational study aimed at identifying the three-dimensional structural prop...
We present a combined computational study aimed at identifying the three-dimensional structural prop...
Rational conversion of biologically active peptides to nonpeptide compounds with retained activity i...
AbstractThe drug:membrane interactions for the antihypertensive AT1 antagonist losartan, the prototy...
When a small molecule binds to the androgen receptor (AR), a conformational change can occur which i...
The number of solved G-protein-coupled receptor (GPCR) crystal structures has expanded rapidly, but ...
<p>When a small molecule binds to the androgen receptor (AR), a conformational change can occur whic...
While the molecular structures of angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) are ...